Selecta Biosciences Announces Proposed Public Offering of Common Stock
January 22, 2019 16:01 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic...
Selecta Biosciences Expands Potential for ImmTOR™ Platform and Streamlined Structure Under Leadership of New CEO, Carsten Brunn, Ph.D.
January 03, 2019 16:11 ET
|
Selecta Biosciences, Inc.
Reported completion of SEL-212 Phase 2 study with positive efficacy and tolerability results observed in the clinical trial, in addition to monthly dosing, indicating potential to serve unmet need for...
Selecta Biosciences Announces New Employment Inducement Grants
December 03, 2018 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Announces Third Quarter 2018 Financial Results and Provides Corporate Update
November 08, 2018 08:00 ET
|
Selecta Biosciences, Inc.
Prioritized head-to-head superiority clinical trial of SEL-212 compared to Krystexxa, expected to begin in the first quarter of 2019 as part of overall planned Phase 3 clinical development program...
Selecta Biosciences to Present at the Stifel Healthcare Conference 2018
November 06, 2018 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Report Third Quarter 2018 Financial Results and Update on SEL-212 Development Strategy, including Planned Head-to-Head Study versus Krystexxa
November 01, 2018 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Presents New Interim Data from Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at ACR 2018
October 23, 2018 07:05 ET
|
Selecta Biosciences, Inc.
Interim analysis indicates serum uric acid (SUA) control has been maintained into months four and five with once monthly combination treatment, SUA control projected to be 66% at end of study...
Selecta Biosciences to Present New Five Monthly Dose Phase 2 Data for SEL-212 in Chronic, Severe Gout at Upcoming 2018 ACR Annual Meeting
October 16, 2018 08:00 ET
|
Selecta Biosciences, Inc.
Data continue to suggest sustained serum uric acid (sUA) level reductions and low number of flares over five months of treatmentResults correlated with low or no anti-drug antibodies (ADAs) against...
Co-administration of AAV Vectors with SVP-Rapamycin Enables Vector Re-administration in Pre-clinical Gene Therapy Study Published in Nature Communications by Généthon and Selecta Biosciences
October 05, 2018 10:01 ET
|
Selecta Biosciences, Inc.; Généthon
Represents a potentially powerful strategy to modulate vector immunogenicity and may open new therapeutic avenues for AAV vector-mediated gene transfer EVRY, France and WATERTOWN, Mass., Oct. 05,...
Selecta Biosciences Appoints Carsten Brunn, Ph.D. as President and Chief Executive Officer
September 27, 2018 07:30 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic...